SCHEDULE: ADAR1 Entities Disclose 9.9% Stake in Inhibikase

ADAR1 Capital Management, its general partner, and Daniel Schneeberger have disclosed a 9.9% beneficial ownership stake in Inhibikase Therapeutics, Inc. as of June 30, 2025.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger collectively reported beneficial ownership of 9.9% of Inhibikase Therapeutics, Inc.'s Common Stock.
• As of June 30, 2025, ADAR1 Capital Management, LLC and Daniel Schneeberger beneficially owned 7,682,503 shares, representing 9.9% of the class.
• This ownership includes 4,113,888 shares held by ADAR1 Partners, LP, 497,268 shares by Spearhead Insurance Solutions IDF, LLC, 510,949 shares by ADAR1 SPV I, LP, and 2,560,398 shares underlying milestone warrants.
• ADAR1 Capital Management GP, LLC beneficially owned 7,737,694 shares, also representing 9.9% of the class, including 4,113,888 shares held by ADAR1 Partners, LP, 510,949 shares by ADAR1 SPV I, LP, and 3,112,857 shares underlying milestone warrants.
• The beneficial ownership calculation is based on 74,341,540 shares of Inhibikase Therapeutics, Inc. Common Stock outstanding as of March 31, 2025, as reported in the Issuer's Form 10-Q filed on May 14, 2025.
• Excluded from the reported beneficial ownership are additional shares underlying milestone warrants (4,693,058 for ADAR1 Capital Management/Schneeberger and 3,422,498 for ADAR1 Capital Management GP) due to a 9.99% beneficial ownership limitation on their exchange and exercise.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.

Risks

• The exercise of certain milestone warrants is subject to a 9.99% beneficial ownership limitation, which could restrict the reporting persons from increasing their stake beyond this threshold immediately.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment manager and its affiliates, indicating a passive investment stake in Inhibikase Therapeutics, Inc. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a substantial stake held by ADAR1 entities.

Key Dates

Keywords

Inhibikase Therapeutics, ADAR1 Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, SEC Filing